The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2010 Apr 7

PMID 20369024

Citations 130

Authors

Bimmi Shrestha

James D Brien

Soila Sukupolvi-Petty

S Kyle Austin

Melissa A Edeling

Taekyung Kim

Katie M OBrien

Christopher A Nelson

Syd Johnson

Daved H Fremont

Michael S Diamond

Affiliations

Soon will be listed here.

Abstract

Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.

Citing Articles

A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.

Kuhn R, Barrett A, DeSilva A, Harris E, Kramer L, Montgomery R J Infect Dis. 2023; 228(Suppl 6):S398-S413.

PMID: 37849402 PMC: 10582523. DOI: 10.1093/infdis/jiad193.

Computer-aided Affinity Enhancement of a Cross-reactive Antibody against Dengue Virus Envelope Domain III.

Jonniya N, Poddar S, Mahapatra S, Kar P Cell Biochem Biophys. 2023; 81(4):737-755.

PMID: 37735329 DOI: 10.1007/s12013-023-01175-8.

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.

Sarker A, Dhama N, Gupta R Front Immunol. 2023; 14:1200195.

PMID: 37334355 PMC: 10272415. DOI: 10.3389/fimmu.2023.1200195.

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement.

Chen Q, Li R, Wu B, Zhang X, Zhang H, Chen R Front Immunol. 2023; 14:1193175.

PMID: 37275868 PMC: 10235449. DOI: 10.3389/fimmu.2023.1193175.

Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.

Cao L, Yu Z, He H, Guo X, Wei C, Zhang X Front Vet Sci. 2023; 10:1137392.

PMID: 37124563 PMC: 10132138. DOI: 10.3389/fvets.2023.1137392.

References

Seif S, Morita K, Matsuo S, Hasebe F, Igarashi A . Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine. 1995; 13(16):1515-21. DOI: 10.1016/0264-410x(95)00097-k. View

Cherrier M, Kaufmann B, Nybakken G, Lok S, Warren J, Chen B . Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009; 28(20):3269-76. PMC: 2771083. DOI: 10.1038/emboj.2009.245. View

Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y . Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol. 2009; 83(9):4338-44. PMC: 2668458. DOI: 10.1128/JVI.02574-08. View

Crill W, Chang G . Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004; 78(24):13975-86. PMC: 533943. DOI: 10.1128/JVI.78.24.13975-13986.2004. View

Kuhn R, Zhang W, Rossmann M, Pletnev S, Corver J, Lenches E . Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5):717-25. PMC: 4152842. DOI: 10.1016/s0092-8674(02)00660-8. View

Yu I, Zhang W, Holdaway H, Li L, Kostyuchenko V, Chipman P . Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008; 319(5871):1834-7. DOI: 10.1126/science.1153264. View

Sanchez M, Pierson T, McAllister D, Hanna S, Puffer B, Valentine L . Characterization of neutralizing antibodies to West Nile virus. Virology. 2005; 336(1):70-82. DOI: 10.1016/j.virol.2005.02.020. View

Li L, Lok S, Yu I, Zhang Y, Kuhn R, Chen J . The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008; 319(5871):1830-4. DOI: 10.1126/science.1153263. View

Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E . Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007; 26(6):361-7. DOI: 10.1089/dna.2006.0547. View

10.

Crill W, Hughes H, Delorey M, Chang G . Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009; 4(4):e4991. PMC: 2659788. DOI: 10.1371/journal.pone.0004991. View

11.

Beasley D, Aaskov J . Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology. 2001; 279(2):447-58. DOI: 10.1006/viro.2000.0721. View

12.

Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P . Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2288-94. DOI: 10.1107/S0907444904023716. View

13.

Kaufman B, Summers P, Dubois D, Eckels K . Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg. 1987; 36(2):427-34. DOI: 10.4269/ajtmh.1987.36.427. View

14.

Sultana H, Foellmer H, Neelakanta G, Oliphant T, Engle M, Ledizet M . Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol. 2009; 183(1):650-60. PMC: 3690769. DOI: 10.4049/jimmunol.0900093. View

15.

Brandriss M, Schlesinger J, Walsh E, Briselli M . Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol. 1986; 67 ( Pt 2):229-34. DOI: 10.1099/0022-1317-67-2-229. View

16.

Pierson T, Xu Q, Nelson S, Oliphant T, Nybakken G, Fremont D . The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007; 1(2):135-45. PMC: 2656919. DOI: 10.1016/j.chom.2007.03.002. View

17.

Gould L, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M . Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol. 2005; 79(23):14606-13. PMC: 1287547. DOI: 10.1128/JVI.79.23.14606-14613.2005. View

18.

Barton G . ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng. 1993; 6(1):37-40. DOI: 10.1093/protein/6.1.37. View

19.

Yasui K . Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol. 1988; 141(10):3606-10. View

20.

Rajamanonmani R, Nkenfou C, Clancy P, Yau Y, Shochat S, Sukupolvi-Petty S . On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol. 2009; 90(Pt 4):799-809. PMC: 2889437. DOI: 10.1099/vir.0.006874-0. View